Bioventus Inc. BVS
NASDAQ
| 06/27/2026 | 03/28/2026 | 12/31/2025 | 09/27/2025 | 06/28/2025 | |
|---|---|---|---|---|---|
| Net Income | 33.44M | 3.11M | 14.76M | 3.16M | 7.46M |
| Total Depreciation and Amortization | 10.95M | 11.21M | -14.02M | 11.40M | 12.05M |
| Total Amortization of Deferred Charges | -- | -- | 3.63M | -- | -- |
| Total Other Non-Cash Items | -14.35M | 4.79M | 27.39M | 4.86M | 5.95M |
| Change in Net Operating Assets | -10.17M | -10.18M | 6.21M | 10.68M | 477.00K |
| Cash from Operations | 19.87M | 8.93M | 37.97M | 30.10M | 25.94M |
| Capital Expenditure | -960.00K | -574.00K | -580.00K | -473.00K | -683.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 0.00 | 0.00 | -686.00K |
| Other Investing Activities | -1.50M | -- | -- | -- | -- |
| Cash from Investing | -2.46M | -574.00K | -580.00K | -473.00K | -1.37M |
| Total Debt Issued | -- | -- | 0.00 | 61.91M | 0.00 |
| Total Debt Repaid | -23.75M | -22.00M | -28.75M | -15.30M | -5.00M |
| Issuance of Common Stock | 853.00K | 120.00K | 511.00K | 96.00K | 1.32M |
| Repurchase of Common Stock | -294.00K | -1.04M | 0.00 | -9.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -241.00K | -220.00K | -208.00K | -66.67M | -10.98M |
| Cash from Financing | -23.43M | -23.14M | -28.45M | -19.98M | -14.66M |
| Foreign Exchange rate Adjustments | -370.00K | -608.00K | 133.00K | -394.00K | 202.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.39M | -15.39M | 9.07M | 9.25M | 10.11M |